Patients Stopping Slimming Medications Put On Weight Four Times Faster Compared to People Using Diet and Exercise

Fresh analysis suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end conventional lifestyle programs.

Research printed in a prominent health publication demonstrates that while overweight individuals can lose about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.

"Individuals buying such medications should be cognizant of the potential of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.

This pace of regain means a return to starting weight in about a year and a half.

Analyzing Approaches

The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.

Researchers point out that individuals who lose weight through dieting usually see a more gradual creep back—perhaps 0.1 kg a month—post-intervention.

Understanding the Fast Rebound

Doctors believe the mode of action of the jabs accounts for the amplified regain.

These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.

"Long-term administration of the hormone concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.

"Stopping of this hormone supplement results in appetite is no longer kept in check, making binge eating much more probable."

An Ongoing Condition?

Health authorities advise the injections for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.

A number of clinicians contend that, due to the high risk of relapse, the therapy might need to be long-term.

This opinion is reinforced by pharmaceutical companies, who note that the findings "emphasize the long-term character of excess weight," comparing it to managing conditions like high blood pressure.

User Testimonies

Users who have stopped the jabs report a sudden return of cravings.

"I experienced a switch flipping and I was suddenly starving," recalled a patient.

This difficulty is worsened if users have not developed lasting dietary or behavioural changes during therapy.

Growing Interest

Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.

• Adoption is greater among females than men.
• The middle-aged age group shows the greatest level of interest.
• Many obtain the drugs through private healthcare rather than the NHS.

Ultimately, experts emphasize that while these medications are effective agents for weight loss, they are not a permanent fix and lasting health benefits hinges on combined behavioural management.